Expanding Leadership Positions Seek to Maximize Hematology/Oncology Progress
In October, Golisano Children’s Hospital welcomes two new leaders to its Division of Pediatric Hematology/Oncology: Dr. Jamie Flerlage and Dr. Jeffrey Andolina. Both are renowned pediatric hematologist/oncologists, bringing their expertise and vision to advance care, research, and education in this specialized field dedicated to treating children with blood disorders and cancer.
Dr. Jamie Flerlage, starting her new roles on October 1, has been appointed as the division chief and academic director of the Division of Pediatric Hematology/Oncology at Golisano Children’s Hospital. She is internationally recognized for her expertise in pediatric Hodgkin's lymphoma and will lead national and international groups focused on research and clinical trials for this disease.
In her new roles, Dr. Flerlage will work to expand external and collaborative clinical research opportunities in Rochester and beyond. She will also serve as an assistant director of Clinical Research within Wilmot Cancer Institute's Clinical Trials Office (CTO). Dr. Jonathan W. Friedberg, MD, MMSc, director of Wilmot Cancer Institute, expressed his excitement, stating that having Dr. Flerlage in Rochester will be a tremendous asset for their clinical research efforts, particularly for childhood cancers.
Dr. Flerlage's expertise is expected to strengthen the clinical trials offered at Wilmot and GCH. Prior to her appointment at Golisano Children’s Hospital and Wilmot, she trained in pediatric hematology/oncology at St. Jude Children’s Research Hospital and became a faculty member there.
Dr. Jeffrey Andolina, the clinical director of Pediatric Hematology and Oncology at Golisano Children’s Hospital, is known for his work in clinical care as well as research in hematologic diseases and cancer affecting children. He has a strong background in developing innovative treatments and improving patient outcomes. In his leadership role, Dr. Andolina will direct inpatient and outpatient clinical services for the division, lead clinical program development, and promote a unified approach to the medical care of pediatric hematology/oncology patients.
Dr. Andolina's research interests include improving bone-marrow transplantation outcomes for children and young adults and evaluating reduced-intensity conditioning regimens for pediatric patients with malignant and non-malignant diseases, especially sickle cell anemia.
Jill Halterman, MD, MPH, interim chair of the Department of Pediatrics, believes that with the leadership of Dr. Andolina and Dr. Flerlage, the division will continue to make progress in its clinical mission and develop advanced treatments to serve children in New York State and beyond. Both Dr. Andolina and Dr. Flerlage are expected to advance Golisano Children’s Hospital’s growing reputation in the field of pediatric cancer.
The Division of Pediatric Hematology/Oncology at Golisano Children’s Hospital was nationally ranked in 2023 by U.S. News & World Report. With the addition of Dr. Flerlage and Dr. Andolina, the division aims to enhance multidisciplinary care, expand research initiatives, and foster a supportive environment for families and young patients facing serious medical challenges.
- Dr. Jamie Flerlage's appointment as division chief and academic director at Golisano Children’s Hospital will involve leading national and international groups focused on research and clinical trials for pediatric Hodgkin's lymphoma, contributing to the advancement of science in health-and-wellness, particularly in the field of cancer.
- As the clinical director of Pediatric Hematology and Oncology at Golisano Children’s Hospital, Dr. Jeffrey Andolina's research interests include improving bone-marrow transplantation outcomes for children and young adults, which aligns with the field of medical-conditions and finance, as advancements in medicine often require substantial investments.
- Jill Halterman, interim chair of the Department of Pediatrics, expects the joint leadership of Dr. Andolina and Dr. Flerlage to further strengthen the clinical trials offered at Wilmot and GCH, contributing to the hospital's growing reputation in the business sector, particularly in the treatment of children's cancer.
